Clinical Trial Update: Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age [Phase 1, Phase 2]

View source ↗

Summary

This trial evaluated Burosumab in infants under 1 year with X-linked hypophosphatemia to assess safety, tolerability, pharmacokinetics and efficacy; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Hypophosphatemia

Drugs mentioned

• Burosumab (burosumab)

Snippet

Sponsor: Kyowa Kirin Pharmaceutical Development Ltd | Conditions: X-linked Hypophosphatemia (XLH) | Phase 1, Phase 2 | Status: COMPLETED